Even a 16% reduction in cardiovascular events may not be enough to secure reimbursement

Ticagrelor (Brilinta / Brilique) was recently approved by the FDA, and is set for launch in the USA. The PLATO trial demonstrated that ticagrelor significantly reduced cardiovascular events (myocardial infarction, stroke and vascular death) by 16% compared with clopidogrel (Plavix).  The … Continue reading